Physician profile
Randy J Epstein
NPI 1427039825
$7,817.94
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,085 · 2020: $293 · 2021: $244 · 2022: $858 · 2023: $3,496 · 2024: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,906 · Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,905.70 |
| Food and Beverage | $1,432.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,501.88 | 2019-2024 | Clareon, Ngenuity, Centurion |
| Rxsight INC | $450.95 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Carl Zeiss Meditec USA, INC. | $235.61 | 2021-2023 | Visumax |
| Novartis Pharmaceuticals Corporation | $233.65 | 2019-2023 | |
| Glaukos Corporation | $221.52 | 2021-2023 | Photrexa Cross-Linking Kit, Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Allergan, INC. | $113.76 | 2019-2021 | |
| Harrow Eye, LLC | $112.61 | 2024 | Vevye |
| Dompe US, INC. | $103.62 | 2019 | |
| The Cameron-Ehlen Group, INC. | $97.19 | 2019-2020 | |
| Biotissue Holdings INC. | $85.35 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $75.99 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $72.49 | 2019-2023 | Cequa |
| Horizon Therapeutics Plc | $69.60 | 2021-2023 | Tepezza |
| New World Medical,INC. | $63.94 | 2023-2024 | Streamline, Kahook Dual Blade, Clearpath |
| Eyevance Pharmaceuticals LLC | $55.96 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $55.52 | 2023 | Vyzulta, Miebo |
| Shire North American Group INC | $54.44 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.32 | 2019-2020 | |
| Ocular Therapeutix, INC. | $38.26 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $29.18 | 2020 | |
| Quidel Corporation | $28.67 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $20.74 | 2024 | Xdemvy |
| Abbvie INC. | $19.80 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $18.39 | 2022 | |
| Oyster Point Pharma, INC. | $13.50 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.